Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Up 889.8% in March

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 48,500 shares, a growth of 889.8% from the February 28th total of 4,900 shares. Based on an average trading volume of 820,700 shares, the short-interest ratio is currently 0.1 days. Approximately 3.0% of the company’s stock are short sold.

Institutional Investors Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 76.14% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of Galmed Pharmaceuticals in a research note on Thursday, March 20th. They issued a “sell” rating on the stock.

Galmed Pharmaceuticals Trading Down 1.1 %

NASDAQ GLMD traded down $0.02 on Wednesday, hitting $1.74. 57,928 shares of the stock traded hands, compared to its average volume of 899,528. The company has a market capitalization of $1.12 million, a P/E ratio of -0.10 and a beta of 0.72. The stock has a 50-day moving average of $2.42 and a 200 day moving average of $3.39. Galmed Pharmaceuticals has a twelve month low of $1.67 and a twelve month high of $23.80.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.